Cargando…

In vitro and in vivo effects of a recombinant anti-PSMA immunotoxin in combination with docetaxel against prostate cancer

Docetaxel (DOC) is used for the first-line treatment of castration resistant prostate cancer (CPRC). However, the therapeutic effects are limited, only about one half of patients respond to the therapy and severe side effects possibly lead to discontinuation of treatment. Therefore, actual research...

Descripción completa

Detalles Bibliográficos
Autores principales:	Michalska, Marta, Schultze-Seemann, Susanne, Bogatyreva, Lioudmila, Hauschke, Dieter, Wetterauer, Ulrich, Wolf, Philipp
Formato:	Online Artículo Texto
Lenguaje:	English
Publicado:	Impact Journals LLC 2016
Materias:	Research Paper
Acceso en línea:	https://www.ncbi.nlm.nih.gov/pmc/articles/PMC5008379/ https://www.ncbi.nlm.nih.gov/pubmed/26968813 http://dx.doi.org/10.18632/oncotarget.8001

Ejemplares similares

An Anti-PSMA Immunotoxin Reduces Mcl-1 and Bcl2A1 and Specifically Induces in Combination with the BAD-Like BH3 Mimetic ABT-737 Apoptosis in Prostate Cancer Cells
por: Masilamani, Anie P., et al.
Publicado: (2020)

Diagnostic Accuracy of Ga-68-HBED-CC-PSMA-Ligand-PET/CT before Salvage Lymph Node Dissection for Recurrent Prostate Cancer
por: Jilg, Cordula A., et al.
Publicado: (2017)

Enhanced cytotoxicity of a Pseudomonas Exotoxin A based immunotoxin against prostate cancer by addition of the endosomal escape enhancer SO1861
por: Masilamani, Anie P., et al.
Publicado: (2023)

A Single-Domain Antibody-Based Anti-PSMA Recombinant Immunotoxin Exhibits Specificity and Efficacy for Prostate Cancer Therapy
por: Xing, Yutong, et al.
Publicado: (2021)

Results of a randomized controlled trial analyzing telemedically supported case management in the first year after living donor kidney transplantation - a budget impact analysis from the healthcare perspective
por: Kaier, Klaus, et al.
Publicado: (2017)

In vivo solid tumor targeting with recombinant VEGF-diphtheria immunotoxin
por: Hosseininejad-Chafi, Mohammad, et al.
Publicado: (2022)

Results from extended lymphadenectomies with [(111)In]PSMA-617 for intraoperative detection of PSMA-PET/CT-positive nodal metastatic prostate cancer
por: Jilg, Cordula A., et al.
Publicado: (2020)

Comparison of (68)Ga-HBED-CC PSMA-PET/CT and multiparametric MRI for gross tumour volume detection in patients with primary prostate cancer based on slice by slice comparison with histopathology
por: Zamboglou, Constantinos, et al.
Publicado: (2017)

Clinical targeting recombinant immunotoxins for cancer therapy
por: Li, Meng, et al.
Publicado: (2017)

Mesothelin-Targeted Recombinant Immunotoxins for Solid Tumors
por: Hagerty, Brendan L., et al.
Publicado: (2020)

Development of Recombinant Immunotoxins for Hairy Cell Leukemia
por: Kreitman, Robert J., et al.
Publicado: (2020)

PSMA-Directed CAR T Cells Combined with Low-Dose Docetaxel Treatment Induce Tumor Regression in a Prostate Cancer Xenograft Model
por: Alzubi, Jamal, et al.
Publicado: (2020)

(99m)Tc-labelled PSMA ligand for radio-guided surgery in nodal metastatic prostate cancer: proof of principle
por: Mix, Michael, et al.
Publicado: (2021)

Diabetes and beta-adrenergic blockage are risk factors for metastatic prostate cancer
por: Krönig, Malte, et al.
Publicado: (2017)

Quantification of recombinant immunotoxin delivery to solid tumors allows for direct comparison of in vivo and in vitro results
por: Mason-Osann, Emily, et al.
Publicado: (2015)

BCG Induced Necrosis of the Entire Bladder Urothelium
por: Krönig, Malte, et al.
Publicado: (2015)

Anti-tumor effects of a recombinant anti-prostate specific membrane antigen immunotoxin against prostate cancer cells
por: Meng, Ping, et al.
Publicado: (2017)

Hosts for Hostile Protein Production: The Challenge of Recombinant Immunotoxin Expression
por: Zuppone, Stefania, et al.
Publicado: (2019)

A bispecific diabody directed against prostate-specific membrane antigen and CD3 induces T-cell mediated lysis of prostate cancer cells
por: Bühler, P., et al.
Publicado: (2007)

Synergistic Cytotoxicity of a Toxin Targeting the Epidermal Growth Factor Receptor and the Glycosylated Triterpenoid SO1861 in Prostate Cancer
por: Fischer, Alexandra, et al.
Publicado: (2023)

Enhanced expression of IFN- γ mRNA in CD4(+)or CD8(+)tumour-infiltrating lymphocytes compared to peripheral lymphocytes in patients with renal cell cancer
por: Elsässer-Beile, U, et al.
Publicado: (2000)

Diagnostic Accuracy of Robot-Guided, Software Based Transperineal MRI/TRUS Fusion Biopsy of the Prostate in a High Risk Population of Previously Biopsy Negative Men
por: Kroenig, Malte, et al.
Publicado: (2016)

Construction, Expression, and Characterization of a Recombinant Immunotoxin Targeting EpCAM
por: Lv, Minghua, et al.
Publicado: (2015)

Evaluation of Hydra HALT-1 as a toxin moiety for recombinant immunotoxin
por: Jiemy, William F., et al.
Publicado: (2020)

Recombinant immunotoxins development for HER2-based targeted cancer therapies
por: Mahmoudi, Reza, et al.
Publicado: (2021)

Synergistic anti-cancer effects of immunotoxin and cyclosporin in vitro and in vivo
por: Andersson, Y, et al.
Publicado: (2009)

Drug Conjugates Such as Antibody Drug Conjugates (ADCs), Immunotoxins and Immunoliposomes Challenge Daily Clinical Practice
por: Janthur, Wolf-Dieter, et al.
Publicado: (2012)

Recombinant Immunotoxin Therapy of Glioblastoma: Smart Design, Key Findings, and Specific Challenges
por: Zhu, Shaowei, et al.
Publicado: (2017)

Evaluating the influence of common antibiotics on the efficacy of a recombinant immunotoxin in tissue culture
por: Zhu, Yuyi, et al.
Publicado: (2019)

Strategies to mitigate the on- and off-target toxicities of recombinant immunotoxins: an antibody engineering perspective
por: Li, Mengyu, et al.
Publicado: (2022)

Immunotoxins: experimental design
por: Dall, P, et al.
Publicado: (2001)

Immunotoxins: The Role of the Toxin (†)
por: Antignani, Antonella, et al.
Publicado: (2013)

Countering immunotoxin immunogenicity
por: Flavell, David J
Publicado: (2016)

Enzalutamide Enhances PSMA Expression of PSMA-Low Prostate Cancer
por: Staniszewska, Magdalena, et al.
Publicado: (2021)

A Multi-Institutional Analysis of Prostate Cancer Patients With or Without 68Ga-PSMA PET/CT Prior to Salvage Radiotherapy of the Prostatic Fossa
por: Schmidt-Hegemann, Nina-Sophie, et al.
Publicado: (2021)

Recombinant immunotoxin targeting GPC3 is cytotoxic to H446 small cell lung cancer cells
por: Rodakowska, Ewelina, et al.
Publicado: (2021)

Radioenhancement with the Combination of Docetaxel and Ultrasound Microbubbles: In Vivo Prostate Cancer
por: Almasri, Firas, et al.
Publicado: (2023)

Interactions Between Pseudomonas Immunotoxins and the Plasma Membrane: Implications for CAT-8015 Immunotoxin Therapy
por: Bokori-Brown, Monika, et al.
Publicado: (2018)

Perioperative cytokine profile during lung surgery predicts patients at risk for postoperative complications—A prospective, clinical study
por: Kaufmann, Kai B., et al.
Publicado: (2018)

Treatment of solid tumors with immunotoxins
por: Messmer, Davorka, et al.
Publicado: (2005)

Cannot write session to /tmp/vufind_sessions/sess_92483moe4tcmp5frvqcqe9a8rh